NCT07169331 2025-12-19A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström MacroglobulinemiaBeOne MedicinesPhase 4 Recruiting18 enrolled
NCT04042376 2025-05-25A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)Janssen Research & Development, LLCPhase 4 Completed17 enrolled 15 charts